The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Until today this year the stock’s price performance recorded a decrease of -19.76%. However, over the last six months, the performance has been stronger by -0.31%. The price of APLS decreased -14.63% over the last 30 days. And in the last five days, it has fallen by -15.50%.
Apellis Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $94.75 on 06/14/23 and the lowest value was $19.83 on 08/07/23.
52-week price history of APLS Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Apellis Pharmaceuticals Inc’s current trading price is -49.31% away from its 52-week high, while its distance from the 52-week low is 142.21%. The stock’s price range during this time has been between $19.83 and $94.75. The trading volume for the Healthcare sector company’s shares reached about 1.68 million for the day, which was higher than the average daily volume of 1.37 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Apellis Pharmaceuticals Inc (APLS) has experienced a quarterly decline of -27.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.79B and boasts a workforce of 706 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 60.89, with a change in price of -1.33. Similarly, Apellis Pharmaceuticals Inc recorded 1,807,781 in trading volume during the last 100 days, posting a change of -2.69%.
APLS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for APLS stands at 0.57. Similarly, the long-term debt-to-equity ratio is also 0.54.
APLS Stock Stochastic Average
Today, Apellis Pharmaceuticals Inc’s raw stochastic average for the past 50 days stands at 0.29%, indicating a decline from the raw stochastic average of the last 20 days, which was 0.59%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 10.97% and 16.95% respectively.
